PMID- 33497055
OWN - NLM
STAT- MEDLINE
DCOM- 20210129
LR  - 20220420
IS  - 0019-1442 (Print)
IS  - 0019-1442 (Linking)
VI  - 74
IP  - 1-2
DP  - 2021 Jan 30
TI  - Matrix metalloproteinases and their tissue inhibitors in relapsing remitting 
      multiple sclerosis: Possible markers and treatment agents.
PG  - 50-56
LID - 10.18071/isz.74.0050 [doi]
AB  - BACKGROUND AND PURPOSE: Matrix metalloproteinases (MMPs), which are synthesized 
      by many cell groups and responsible for the destruction of matrix proteins, and 
      endogen tissue inhibitors of MMPs (TIMPs) have a role in the pathogenesis of 
      Multiple Sclerosis (MS) by affecting the blood-brain barrier. We aimed to 
      investigate the role of MMPs and TIMPs in the immunopathogenesis and in the 
      course of multiple sclerosis (MS). METHODS: We enrolled 25 relapsing remitting MS 
      patients, who had a definite MS diagnosis according to McDonald criteria and 25 
      healthy subjects similar for age and gender as control group. MMP-9- and TIMP-1 
      levels were measured twice in patient group (one time during an attack and one in 
      remission) and once in healthy subjects. RESULTS: MMP-9- and TIMP-levels of 
      patients during attack and remission period and MMP-9/TIMP-1 ratio were found 
      significantly higher than in the control subjects. In patient group MMP-9 and 
      TIMP-1 levels and MMP-9/TIMP-1 ratio during attacks were not significantly 
      different than during remission period. However, when subdivided according to 
      their number of attacks, patients with 2 attacks had significantly higher levels 
      during attack period comparing to remission period (p<0.05); in case of patients 
      with more than 2 attacks did not have a statistically significant difference in 
      attack and remission periods. CONCLUSION: Matrix metalloproteinases are important 
      actors in MS immunopathogenesis, particularly in the early period and inhibitor 
      agents for these enzymes can be used as a treatment option.
FAU - Sanli, Arzu
AU  - Sanli A
AD  - Department of Neurology, Bakirkoy Research and Training Hospital for Neurology 
      and Psychiatry, Istanbul, Turkey.
FAU - Ozturk, Musa
AU  - Ozturk M
AD  - Department of Neurology, Bakirkoy Research and Training Hospital for Neurology 
      and Psychiatry, Istanbul, Turkey.
FAU - Soysal, Aysun
AU  - Soysal A
AD  - Department of Neurology, Bakirkoy Research and Training Hospital for Neurology 
      and Psychiatry, Istanbul, Turkey.
FAU - Doventas, Yasemin
AU  - Doventas Y
AD  - Department of Biochemistry, Haseki Research and Training Hospital, Istanbul, 
      Turkey.
FAU - Basoglu, Fulya
AU  - Basoglu F
AD  - Department of Neurology, Bakirkoy Research and Training Hospital for Neurology 
      and Psychiatry, Istanbul, Turkey.
FAU - Gozubatik-Celik, Gokcen R
AU  - Gozubatik-Celik GR
AUID- ORCID: 0000-0002-8186-8703
AD  - Department of Neurology, Bakirkoy Research and Training Hospital for Neurology 
      and Psychiatry, Istanbul, Turkey.
FAU - Baybas, Sevim
AU  - Baybas S
AD  - Department of Neurology, Bakirkoy Research and Training Hospital for Neurology 
      and Psychiatry, Istanbul, Turkey.
LA  - eng
PT  - Journal Article
TT  - Matrix metalloproteinazok es szoveti inhibitoraik relapszalo-remittalo sclerosis 
      multiplexben: lehetseges biomarkerek es kezelesi formak.
PL  - Hungary
TA  - Ideggyogy Sz
JT  - Ideggyogyaszati szemle
JID - 17510500R
RN  - 0 (TIMP1 protein, human)
RN  - 0 (Tissue Inhibitor of Metalloproteinase-1)
RN  - EC 3.4.24.35 (MMP9 protein, human)
RN  - EC 3.4.24.35 (Matrix Metalloproteinase 9)
SB  - IM
MH  - Humans
MH  - Matrix Metalloproteinase 9
MH  - *Multiple Sclerosis, Relapsing-Remitting/drug therapy
MH  - Tissue Inhibitor of Metalloproteinase-1
OTO - NOTNLM
OT  - MMP-9
OT  - TIMP-1
OT  - matrix metalloproteinase-9
OT  - multiple sclerosis
OT  - tissue inhibitors of MMPs
EDAT- 2021/01/27 06:00
MHDA- 2021/01/30 06:00
CRDT- 2021/01/26 12:13
PHST- 2021/01/26 12:13 [entrez]
PHST- 2021/01/27 06:00 [pubmed]
PHST- 2021/01/30 06:00 [medline]
AID - 10.18071/isz.74.0050 [doi]
PST - ppublish
SO  - Ideggyogy Sz. 2021 Jan 30;74(1-2):50-56. doi: 10.18071/isz.74.0050.